ENDOVASC INC. PRESS RELEASE
ENDOVASC ANNOUNCES CHANGE OF AUDITOR
MONTGOMERY, Texas--Aug. 16, 2005--Endovasc, Inc. (OTCBB: EVSC - News), a
---- ----
business development corporation that pioneers cardiovascular and metabolic drug
therapies, announced today that the Company has retained McConnell & Jones LLP
as its independent accountants to perform the Company's annual and financial
control audits, including quarterly reviews.
McConnell & Jones LLP is a certified public accounting firm based in Houston,
Texas. The experienced team at McConnell & Jones LLP serves a diverse section of
businesses, state and local government agencies, and nonprofit organizations
through a combination of assurance services that includes audits, review
examinations and compilations.
The prior auditor of the Company was Ham, Langston & Brezina. There were no
disputes or disagreements between the Company and the prior auditors relating to
any matters of accounting principle or practice, financial statement disclosure,
or auditing scope or procedure. The Company has authorized the prior auditors to
respond fully to the inquiries of any successor auditor appointed by the
Company.
About Endovasc
Endovasc, Inc., established in 1996, is a Business Development Company focused
on acquiring and investing in innovative drug development in the areas of
cardiovascular and metabolic medicine. Endovasc's subsidiaries include:
Liprostin Inc., which holds the intellectual property for a liposomal based
treatment to increase circulation and reduce leg pain in patients suffering from
vascular disease; Nutraceutical Development Corporation which has an agreement
in place with an innovative product development company to commercialize its
muscle mass enhancing product; and PROStent, a stent coating technology.
For more information about Endovasc, please visit www.endovasc.com.
----------------
Safe Harbor Statement
The foregoing statements are made under the "Safe Harbor" Private Securities
Litigation Reform Act of 1995 and may contain forward-looking statements that
involve risks and uncertainties that may not be evident at the time of this
release. For more information about Endovasc, please visit www.endovasc.com.
- ----------------
Contact:
ZA Consulting LLC
David Zazoff, 212-505-5976
david@za-consulting.net
-----------------------
550 Club Drive, Suite 345 * Montgomery, TX 77316 * 936.582.5920 * Fax:
936.582.5996 * Web: www.endovasc.com